Press Release
« Back |
View printer-friendly version |
– Cabozantinib in combination with atezolizumab demonstrated encouraging activity with a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and patients with previously treated advanced non-small cell lung cancer –
UC Cohorts 3, 4 and 5 (abstract 4504):
UC results will be presented by
At a median follow-up of 27.9 months for cohort 3, 19.1 months for cohort 4 and 32.9 months for cohort 5, the primary endpoint of objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator was 20%, 30% and 10%, respectively. Cabozantinib in combination with atezolizumab demonstrated encouraging clinical activity for other endpoints and a manageable safety profile across all three cohorts. See other efficacy outcomes, the most common treatment-related adverse events (AEs) and discontinuation rates in Table 1 below.
“People with advanced bladder cancer face a poor prognosis, meaning new treatment options are needed, both in the first-line setting and after disease progression,” said
TABLE 1 |
Cohort 3 Cisplatin ineligible (N=30) |
Cohort 4 Cisplatin eligible (N=30) |
Cohort 5 Received prior ICI (N=31) |
Efficacy |
|||
Objective response rate (95% CI) |
20% (8-39) |
30% (15-49) |
10% (2-26) |
Disease control rate (95% CI) |
80% (61-92) |
63% (44-80) |
61% (42-78) |
Median duration of response, months (95% CI) |
7.1 (2.8-NE) |
NE (7.2-NE) |
4.1 (2.6-NE) |
Median progression-free survival, months (95% CI) |
5.6 (3.1-11.1) |
7.8 (1.6-13.8) |
3.0 (1.8-5.5) |
Median overall survival, months (95% CI) |
14.3 (8.6-NE) |
13.5 (7.8-23.2) |
8.2 (5.5-9.8) |
AEs |
|||
Any grade treatment-related AE, n (%) |
29 (97) |
28 (93) |
28 (90) |
Diarrhea |
13 (43) |
10 (33) |
11 (35) |
Aspartate aminotransferase increased |
11 (37) |
6 (20) |
6 (19) |
Decreased appetite |
10 (33) |
8 (27) |
12 (39) |
Alanine aminotransferase increased |
9 (30) |
5 (17) |
5 (16) |
Fatigue |
8 (27) |
8 (27) |
15 (48) |
Nausea |
8 (27) |
5 (17) |
8 (26) |
Grade 3/4 treatment-related AE, n (%) |
19 (63) |
13 (43) |
14 (45) |
Grade 5 treatment-related AE, n |
0 |
0 |
0 |
Discontinuations due to treatment-related AEs, n (%) |
|||
Cabozantinib |
8 (27) |
9 (30) |
6 (19) |
Atezolizumab |
5 (17) |
5 (17) |
7 (23) |
Both |
4 (13) |
5 (17) |
6 (19) |
AE=adverse event; CI=confidence interval; ICI=immune checkpoint inhibitor; NE=not evaluable
NSCLC Cohorts 7 and 20 (abstract 9005):
Results for cohorts 7 and 20 will be presented by
At a median follow-up of 24.7 months for cohort 7 and 21.5 months for cohort 20, the primary endpoint of ORR per RECIST version 1.1 by investigator was 19% and 6%, respectively. A manageable safety profile was seen in both cohorts. Other efficacy outcomes, the most common treatment-emergent AEs and discontinuation rates are shown in Table 2 below. In cohort 7, clinical activity was observed with cabozantinib in combination with atezolizumab irrespective of PD-L1 expression.
“We are pleased to present these promising findings of cabozantinib in combination with atezolizumab at ASCO 2022, reinforcing our longstanding commitment to advancing therapies that improve outcomes for those with advanced solid tumors,” said
TABLE 2 |
Cohort 7
|
Cohort 20
|
Efficacy |
||
Objective response rate (95% CI) |
19% (11-29) |
6% (1-21) |
Disease control rate (95% CI) |
80% (70-88) |
65% (45-81) |
Median duration of response, months (95% CI) |
5.8 (4.2-6.9) |
10.6 (6.3-NE) |
Median progression-free survival, months (95% CI) |
4.5 (3.5-5.6) |
3.4 (1.4-5.6) |
Median overall survival, months (95% CI) |
13.8 (7.2-15.7) |
9.4 (4.5-11.7) |
AEs |
||
Any grade treatment-emergent AEs, n (%) |
81 (100) |
31 (100) |
Diarrhea |
36 (44) |
16 (52) |
Decreased appetite |
30 (37) |
11 (35) |
Fatigue |
29 (36) |
11 (35) |
Nausea |
28 (35) |
15 (48) |
Asthenia |
24 (30) |
12 (39) |
Constipation |
21 (26) |
5 (16) |
Pyrexia |
20 (25) |
2 (6) |
Grade 3/4 treatment-emergent AE, n (%) |
43 (53) |
22 (71) |
Grade 5 treatment-related AE, n |
1 |
1 |
Discontinuations due to treatment-related AEs, n (%) |
||
Cabozantinib |
11 (14) |
3 (10) |
Atezolizumab |
8 (10) |
1 (3) |
Both |
5 (6) |
1 (3) |
AE=adverse event; CI=confidence interval; NE=not evaluable
*Includes 8 patients who initiated therapy with cabozantinib plus atezolizumab after experiencing disease progression.
About COSMIC-021
COSMIC-021 is a multicenter, phase 1b, open-label study that enrolled a total of 914 patients. The trial was divided into two parts: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase was designed to enroll patients either with advanced renal cell carcinoma (RCC) with or without prior systemic therapy or with inoperable, locally advanced, metastatic or recurrent UC (including renal, pelvis, ureter, urinary bladder and urethra), after prior platinum-based therapy. Ultimately, all 12 patients who enrolled in this stage of the trial had advanced RCC. The dose-escalation phase of the study determined the recommended dose of cabozantinib to be 40 mg daily when given in combination with atezolizumab (1200 mg infusion once every three weeks).
In the expansion phase, the trial enrolled a total of 902 patients across 23 cohorts in 12 tumor types: RCC, UC, NSCLC, metastatic castration-resistant prostate cancer (CRPC), hepatocellular carcinoma (HCC), triple-negative breast cancer, epithelial ovarian cancer, endometrial cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, head and neck cancer and differentiated thyroid cancer (DTC).
Four of the cohorts were exploratory single-agent cohorts: two in advanced UC or NSCLC, one in advanced CRPC evaluating cabozantinib as a single-agent, and one in advanced CRPC evaluating single-agent atezolizumab.
More information about COSMIC-021 is available at ClinicalTrials.gov.
About UC
UC is the most common type of bladder cancer, accounting for 90% of all cases.1 Bladder cancer is the sixth most common cancer in the
About NSCLC
Lung cancer is the second most common type of cancer in the
About CABOMETYX® (cabozantinib)
In the
CABOMETYX is not indicated as a treatment for metastatic UC or NSCLC.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage and prior to surgery as recommended. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.
Perforations and Fistulas: Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4 fistula or a GI perforation.
Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.
Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.
Diarrhea: Diarrhea occurred in 62% of CABOMETYX patients. Grade 3 diarrhea occurred in 10% of CABOMETYX patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1, resume at a reduced dose.
Palmar-Plantar Erythrodysesthesia (PPE): PPE occurred in 45% of CABOMETYX patients. Grade 3 PPE occurred in 13% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.
Hepatotoxicity: CABOMETYX in combination with nivolumab can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes than when the drugs are administered as single agents. For elevated liver enzymes, interrupt CABOMETYX and nivolumab and consider administering corticosteroids.
With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. ALT or AST >3 times ULN (Grade ≥2) was reported in 83 patients, of whom 23 (28%) received systemic corticosteroids; ALT or AST resolved to Grades 0-1 in 74 (89%). Among the 44 patients with Grade ≥2 increased ALT or AST who were rechallenged with either CABOMETYX (n=9) or nivolumab (n=11) as a single agent or with both (n=24), recurrence of Grade ≥2 increased ALT or AST was observed in 2 patients receiving CABOMETYX, 2 patients receiving nivolumab, and 7 patients receiving both CABOMETYX and nivolumab. Withhold and resume at a reduced dose based on severity.
Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.
Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Adrenal insufficiency led to permanent discontinuation of CABOMETYX and nivolumab in 0.9% and withholding of CABOMETYX and nivolumab in 2.8% of patients with RCC.
Approximately 80% (12/15) of patients with adrenal insufficiency received hormone replacement therapy, including systemic corticosteroids. Adrenal insufficiency resolved in 27% (n=4) of the 15 patients. Of the 9 patients in whom CABOMETYX with nivolumab was withheld for adrenal insufficiency, 6 reinstated treatment after symptom improvement; of these, all (n=6) received hormone replacement therapy and 2 had recurrence of adrenal insufficiency.
Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.
Osteonecrosis of the Jaw (ONJ): ONJ occurred in <1% of CABOMETYX patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold CABOMETYX for development of ONJ until complete resolution, resume at a reduced dose.
Impaired Wound Healing: Wound complications occurred with CABOMETYX. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer CABOMETYX for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic findings on MRI, can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.
Thyroid Dysfunction: Thyroid dysfunction, primarily hypothyroidism, has been observed with CABOMETYX. Based on the safety population, thyroid dysfunction occurred in 19% of patients treated with CABOMETYX, including Grade 3 in 0.4% of patients.
Patients should be assessed for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitored for signs and symptoms of thyroid dysfunction during CABOMETYX treatment. Thyroid function testing and management of dysfunction should be performed as clinically indicated.
Hypocalcemia: CABOMETYX can cause hypocalcemia. Based on the safety population, hypocalcemia occurred in 13% of patients treated with CABOMETYX, including Grade 3 in 2% and Grade 4 in 1% of patients. Laboratory abnormality data were not collected in CABOSUN.
In COSMIC-311, hypocalcemia occurred in 36% of patients treated with CABOMETYX, including Grade 3 in 6% and Grade 4 in 3% of patients.
Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.
Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiating CABOMETYX and advise them to use effective contraception during treatment and for 4 months after the last dose.
ADVERSE REACTIONS
The most common (≥20%) adverse reactions are:
CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, constipation.
CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.
DRUG INTERACTIONS
Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.
Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage.
USE IN SPECIFIC POPULATIONS
Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.
Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.
Please see accompanying full Prescribing Information
https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
About
Founded in 1994,
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of data from UC and NSCLC cohorts of COSMIC-021 during oral abstract sessions at ASCO 2022; the therapeutic potential of cabozantinib in combination with atezolizumab to help patients with advanced cancers who require additional treatment options; Exelixis’ longstanding commitment to advancing therapies that improve outcomes for patients with advanced solid tumors and plans to continuing research for these cancers, including NSCLC; and Exelixis’ plans to reinvest in its business to maximize the potential of the company’s pipeline, including through targeted business development activities and internal drug discovery. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the
COTELLIC is a registered trademark of
MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.
1 Bladder Cancer: Introduction. Cancer.Net website. Available at: https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed
2 Cancer Facts & Figures 2022. ACS website. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf. Accessed
3 Key Statistics for Bladder Cancer. ACS website. Available at: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed
4 Cancer Stat Facts: Bladder Cancer. SEER website. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed
5 Key Statistics for
6 What Is
7
8 Cancer Stat Facts: Lung and Bronchus Cancer. SEER website. Available at: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005695/en/
Investors:
EVP, Public Affairs and
Investor Relations
(650) 837-8194
shubbard@exelixis.com
Media:
Executive Director, Public Affairs
and Advocacy Relations
(650) 837-7522
ltreadway@exelixis.com
Source: